Onconova Therapeutics- Warrants (01/08/2021) Operating Income

The latest operating income for ONTXW is $-7B as of March 2026. That compares with $-37M in the prior-year period — down 18769.0% year over year. Investors often review this figure alongside Onconova Therapeutics- Warrants (01/08/2021)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ONTXW's operating income moved from $-37M to $-7B — a 18769.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Onconova Therapeutics- Warrants (01/08/2021)'s operating scale or balance-sheet position.

A operating income figure of $-7B for ONTXW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ONTXW's operating income ($-7B), review year-over-year change from $-37M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Onconova Therapeutics- Warrants (01/08/2021)'s operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.